Since most luminal BC patients are initially treated with endocrine therapy, we first analyzed the correlation between the response to these therapies (tamoxifen or aromatase inhibitors) and TRIB3 expression in databases from published studies [43]. The gene discussed is CYP19A1; the disease is breast cancer.